A personal Q&A from two patients of psychedelic therapy: Psilocybin for depression – Michael Bourne Michael Bourne is a 57-year-old website designer from the North East of England, who tried several unsuccessful depression treatments, including talking therapy and prescription medications, before turning to psilocybin clinical trials. Michael took part in research into psilocybin treatment for depression in 2015 as part of the clinical trial at Imperial College London. He was transformed and invigorated as a result. The positive effect of psilocybin therapy lasted for almost a year, and has continued to help keep daily life in perspective. Psilocybin treatment has hugely helped him regain his passion for creativity in audio and photography/graphic design. He is currently on the steering committee for the Kings College research into psilocybin therapy for treatment resistant depression. This clinical trial (PsiDeR) is due to start early 2021, and will compare psilocybin therapy to a placebo. Michael is driven to help others who suffer with depression because of how much psilocybin has helped him. Ayahuasca for Trauma and Addiction – Mark Drax Mark Drax is an Addiction Recovery Coach, trained in England and America and based near London. In 2012, he left commerce in search of a more spiritual and healing career related to his own journey through abuse and addiction. He turned his experiences with trauma and addiction into a coaching practice to help hurting men recognise their patterns of destructive behaviour, to unlearn whatever painful emotional myths still lingering from childhood and to start choosing to ‘live’ instead of just to ‘survive’. In 2016, Mark travelled to The Temple of the Way of Light in Iquitos, Peru to participate in an ayahuasca ceremony. Alongside 23 others, he began a 3-week journey in the Peruvian jungle, drinking ayahuasca every third night at the guidance of a shaman. Mark cites these three weeks as life-changing and credits the ayahuasca for tapping into parts of his own psyche that 14 years of treatment had not even approached. This webinar was recorded during a Drug Science Live Event which included a live Q&A session from the audience. If you want to ensure that you don’t miss any of our events, so that you can ask your questions live, all you need to do is join the Drug Science Mailing List. Drug Science is the leading independent scientific body on drugs in the UK. We rely on donations to provide clear, evidence-based information without political or commercial interference. Drug Science webinars are free, and always will be, so if you’d like to support us then please consider joining the Drug Science Community